Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests

Journal of Alzheimer's Disease

Volumn 33, Issue 2, 2013, Pages 451-462

  Bahar Fuchs, Alex ^a,b   Villemagne, Victor ^a,c   Ong, Kevin ^a   Chetélat, Gaël ^d   Lamb, Fiona ^a   Reininger, Cornelia B ^e   Woodward, Michael ^a   Rowe, Christopher C ^a  

^a AUSTIN HEALTH   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d INSERM   (France)

^e BAYER PHARMA AG   (Germany)

Author keywords

Aging; Alzheimer's disease; amyloid imaging; memory; mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CLINICAL ARTICLE; COGNITION; EDUCATIONAL STATUS; EPISODIC MEMORY; FEMALE; GROUPS BY AGE; HIPPOCAMPUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECALL; SENSITIVITY AND SPECIFICITY;

EID: 84872450217     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121315     Document Type: Article

References (41)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
3. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
4. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement 7, 270-279.
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 280-292.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJr,Kawas CH, Klunk WE,Koroshetz WJ, Manly JJ (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 263-269.
7. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368. (Pubitemid 29120041)
8. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE,Mathis CA, Price JC, Masters CL,Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725. (Pubitemid 46763260)
9. Sperling RA, LaViolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178-188.
10. WolkDA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65, 557-568.
11. Villemagne VL, Pike KE, Ch́etelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O(2011) Longitudinal assessment ofAand cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
12. Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC (2008) The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol 38, 1-15.
13. Cummings BJ, Pike CJ, Shankle R, CotmanCW(1996) Betaamyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17, 921-933. (Pubitemid 27022746)
14. Nordahl CW, Ranganath C, Yonelinas AP, DeCarli C, Reed BR, Jagust WJ (2005) Different mechanisms of episodic memory failure in mild cognitive impairment. Neuropsychologia 43, 1688-1697. (Pubitemid 40961689)
15. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844. (Pubitemid 350033975)
16. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
17. Pike KE, Ellis KA, Villemagne VL, Good N, Ch́etelat G, Ames D, Szoeke C, Laws SM (2011) Cognition and betaamyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 49, 2384-2390.
18. Storandt M, Mintun MA, Head D, Morris JC (2009) Cognitive decline and brain volume loss as signatures of cerebral amyloid- peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with A- deposition. Arch Neurol 66, 1476.
19. Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67, 353-364.
20. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, 665-680. (Pubitemid 351294719)
21. Mormino E, Kluth J, Madison C, Rabinovici G, Baker S, Miller B, Koeppe R, Mathis C, Weiner M, Jagust W (2009) Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects. Brain 132, 1310.
22. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61, 378-384. (Pubitemid 38327357)
23. Ch́etelat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN (2011) Independent contribution of temporal -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 134, 798.
24. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
25. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG (2006) Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology 67, 2176-2185. (Pubitemid 46035473)
26. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
27. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414. (Pubitemid 23346995)
28. Saxton J, Ratcliff G,Munro CA, Coffey EC, Becker JT, Fried L,Kuller L (2000) Normative data on the Boston Naming Test and two equivalent 30-item short forms. Clin Neuropsychol 14, 526-534.
29. Wechsler D (1997) WAIS-III Administration and Scoring Manual, The Psychological Corporation, San Antonio.\\
30. Delis D, Kramer J, Kaplan E, Ober B (2000) CVLT-II: California Verbal Learning Test Second Edition Adult Version, The Psychological Corporation, San Antonio.
31. Wechsler D (1997) Wechsler Memory Scale - Third Edition, The Psychological Corporation, San Antonio.
32. Meyers J, Meyers K (1995) Rey Complex Figure Test and Recognition Trial. Psychological Assessment Resources Inc., Odessa.
33. Delis D, Kaplan E, Kramer J (2001) D-KEFS executive function system, The Psychological Corporation, San Antonio.
34. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL (2008) Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7, 129-135.
35. Kovacevic S, Rafii MS, Brewer JB (2009) High-throughput, fully-automated volumetry for prediction ofMMSEand CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 23, 139.
36. Mevel K, Desgranges B, Baron JC, Landeau B, de La Sayette V, Viader F, Eustache F, Ch́etelat G (2011) Which SPM method should be used to extract hippocampal measures in early Alzheimer's disease? J Neuroimage 21, 310-316.
37. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14, 21-36. (Pubitemid 32552740)
38. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC (2011) Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52, 1210-1217.
39. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatrics 21, 672-687.
40. Bobinski M, de Leon MJ, Tarnawski M, Wegiel J, Reisberg B, Miller DC, Wisniewski HM (1998) Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res 805, 267-269. (Pubitemid 29005144)
41. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319. (Pubitemid 38269583)